Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 23, Issue 1, Pages 121-131Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2010.01.007
Keywords
chronic lymphocytic leukaemia; NF-kappa B; drug resistance
Categories
Funding
- CALGB Foundation
- D. Warren Brown Foundation
- Leukemia and Lymphoma Society
- National Cancer Institute [P01 CA95426, T325CA009338, T32 CA106196, P01 CA101956]
Ask authors/readers for more resources
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signalling pathway is constitutively active in a variety of cancers, including chronic lymphocytic leukaemia (CLL). The importance of this signalling pathway identifies it as a prime therapeutic target; however, the complexity and potential side effects of inhibiting NF-kappa B have thus far made the clinical use of NF-kappa B inhibitors a relatively unexplored resource in this disease. This article discusses the role of NF-kappa B in CLL as a common crossroad for pathways promoting drug resistance in CLL. We provide the background on how this pathway contributes to both spontaneous and drug-induced apoptosis. Potential new avenues to regulate this pathway in CLL are also discussed. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available